Why the study?
Does a biodegradable polymer-based sirolimus-eluting stent with 6 months of dual antiplatelet therapy provide sustained safety and efficacy in all-comer patients?
Population
2,077 all-comer patients in routine clinical practice, multinational (4 countries).
Design
Cohort
Follow-up
3 years
Authors
Loading...
Supports 6-month DAPT safety with this stent in real-world patients; leaves open optimal duration pending randomized trials.
Does a biodegradable polymer-based sirolimus-eluting stent with 6 months of dual antiplatelet therapy provide sustained safety and efficacy in all-comer patients?
A biodegradable polymer-based sirolimus-eluting stent with 6 months of dual antiplatelet therapy demonstrates sustained safety and efficacy with low rates of MACE and stent thrombosis at 3 years in a real-world population.
Han et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: